Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL
 | Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL CME, CPE, CNE Julie M. Vose, MD, MB – Chair; Jeremy R. Stone, MD; Nicole Lamanna, MD; Peter Campbell, PharmD, BCOP | |
| Release Date: August 30, 2021 Expiration Date: August 30, 2022 | ||
| Bruton’s tyrosine kinase inhibitor (BTKi) therapy has emerged as a major treatment option for patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL) and other B-cell malignancies that can improve quality of life for patients. To ensure optimal patient outcomes, however, it is essential to maintain ongoing therapy. This requires prompt recognition and management of the unique adverse events (AEs) associated with BTKi therapy. However, data suggest that management of BTKi AEs by health care professionals (HCPs) often diverges from evidence-based expert recommendations, especially grade 3/4 AEs. In this activity, Dr. Vose, Dr. Stone, Dr. Lamanna, and Dr. Campbell discuss the treatment for CLL and MCL and challenges you’re likely to face in your practice this year.
This activity was previously presented as a live webinar. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded. Provided by MediCom Worldwide, Inc. | ||
| View Only, No Credit | ||